Sruthi Meka is a senior associate on the FasterCures team at the Milken Institute. Meka has experience in program evaluation, data analysis, and qualitative research across several academic and nonprofit research settings in public health and health services research.
Managing Director, FasterCures, Milken Institute Health
Sung Hee Choe is the managing director on the FasterCures team at the Milken Institute. She is responsible for overseeing FasterCures' day-to-day operations, setting strategy, and delivering on initiatives in biomedical innovation and global health.
Esther Krofah is the executive vice president of Milken Institute Health, leading FasterCures, Public Health, the Future of Aging, and Feeding Change. She has extensive experience managing efforts to unite diverse stakeholders to solve critical issues and achieve shared goals that improve patients’ lives.
Despite high levels of spending on health care in the United States—almost double that of peer high-income countries—health outcomes continue to lag across a wide range of disease conditions. The differences in the incidence, prevalence, treatment course, and outcomes for various diseases across populations are stark. These disparities are caused by myriad factors, such as social needs, geography, insurance coverage, and income, as well as variations in underlying biology that affect the risk, onset, and severity of both chronic and acute diseases. They are exacerbated by a lack of access to basic health care and to innovative treatments through clinical trials for many populations disproportionately impacted by the burden of disease.
In recent years, the lack of both access to clinical trials and the infrastructure to recruit populations across the US into clinical trials has become a major focus for researchers and clinical trial sponsors. This increased attention reflects a growing understanding that participation across populations strengthens the biomedical innovation ecosystem by improving the generalizability of research findings, boosting confidence in treatment safety and effectiveness, and building trust in the research enterprise.
Given the medical and scientific imperative for representative clinical trials, FasterCures sought to identify actions by clinical trial sponsors, sites, and others in the research ecosystem to increase enrollment of representative populations in clinical research. We also interviewed community-serving and patient advocacy organizations about their perceptions of the effectiveness of these actions.
Through this report, FasterCures aims to highlight current practices and insights from organizations actively engaged in a range of efforts to build collective knowledge and to serve as a resource for stakeholders working to expand access and representation in clinical trials across disease areas, geographies, and populations, all within the constraints of an evolving research environment.
FasterCures at the Milken Institute is honored to provide our response to the Reauthorization of the Prescription Drug User Fee Act; Public Meeting; Request for Comments [FDA–2025–N–0816]. As a nonprofit, nonpartisan think tank, the Milken...
Esther Krofah is the executive vice president of Milken Institute Health, leading FasterCures, Public Health, the Future of Aging, and Feeding Change. She has extensive experience managing efforts to unite diverse stakeholders to solve critical issues and achieve shared goals that improve patients’ lives.
The collapse of US foreign assistance is an opportunity to build a more prosperous world. Once the world’s largest donor, the United States has slashed funding for the US Agency for International Development, President’s Emergency Plan for...
In 2022, FasterCures published a report titled The Current Landscape of the Science of Patient Input, which examined the progress of patient engagement (PE) in biomedical research and identified ways to overcome ongoing challenges. Building...
June 24, 2024 (Washington, DC)— Clinical trials can provide the possibility to obtain novel treatments for conditions and diseases that are not yet commercially available. Yet, these lifesaving treatments are often difficult or impossible...
Paul Guequierre is the director of strategic communications. In this role, he works to increase the profile of Milken Institute in the media, raise the visibility of issues important to the organization and its stakeholders, and expand the Institute's digital presence.
This report details the actions organizations and sectors from across the enterprise can take to create a clinical trials enterprise that is diverse, equitable, inclusive, and accessible to all.
The impact of patient engagement has been demonstrated by numerous case studies for specific diseases and products, as well as a model for the return on investment. There is now a growing call for expanding beyond single examples of patient...
FasterCures, a center of the Milken Institute, designed this guide for patient advocacy organizations that are interested in hosting, or are currently planning, an externally led patient-focused drug development (PFDD) meeting. We have...